Suppr超能文献

包膜病毒在渗透压调节剂溶液中的絮凝与去除

Enveloped virus flocculation and removal in osmolyte solutions.

作者信息

Gencoglu Maria F, Heldt Caryn L

机构信息

Department of Chemical Engineering, Michigan Technological University, 1400 Townsend Dr. Houghton, MI 49931, USA.

Department of Chemical Engineering, Michigan Technological University, 1400 Townsend Dr. Houghton, MI 49931, USA.

出版信息

J Biotechnol. 2015 Jul 20;206:8-11. doi: 10.1016/j.jbiotec.2015.03.030. Epub 2015 Apr 10.

Abstract

Our ability to reduce infectious disease burden throughout the world has been greatly improved by the creation of vaccines. However, worldwide immunization rates are low. The two most likely reasons are the lack of sufficient distribution in underdeveloped countries and the high cost of vaccine products. The high costs are due to the difficulties of manufacturing individual vaccine products with specialized purification trains. In this study, we propose to use virus flocculation in osmolytes, followed by microfiltration, as an alternative vaccine purification operation. In our previous work, we demonstrated that osmolytes preferentially flocculate a non-enveloped virus, porcine parvovirus (PPV). In this work we show that osmolytes flocculate the enveloped virus, Sindbis virus heat resistant strain (SVHR), and demonstrate a >80% removal with a 0.2 μm microfilter membrane while leaving proteins in solution. The best osmolytes were tested for their ability to flocculate SVHR at different concentrations, pH and ionic strengths. Our best removal was 98% of SVHR in 0.3M mannitol at a pH of 5. We propose that osmolytes are able to flocculate hydrophobic non-enveloped and enveloped virus particles by the reduction of the hydration layer around the particles, which stimulates virus aggregation. Now that we have demonstrated that protecting osmolytes flocculate viruses, this method has the potential to be a future platform purification process for vaccines.

摘要

疫苗的发明极大地提高了我们减轻全球传染病负担的能力。然而,全球免疫接种率较低。两个最可能的原因是疫苗在欠发达国家缺乏足够的分发以及疫苗产品成本高昂。成本高昂是由于使用专门的纯化流程生产单个疫苗产品存在困难。在本研究中,我们提议使用渗透压剂中的病毒絮凝,随后进行微滤,作为一种替代的疫苗纯化操作。在我们之前的工作中,我们证明了渗透压剂优先使一种无包膜病毒——猪细小病毒(PPV)发生絮凝。在这项工作中,我们表明渗透压剂能使包膜病毒——辛德毕斯病毒耐热株(SVHR)发生絮凝,并通过0.2μm微滤膜实现了>80%的去除率,同时使蛋白质留在溶液中。测试了最佳渗透压剂在不同浓度、pH值和离子强度下絮凝SVHR的能力。我们在pH值为5的0.3M甘露醇中对SVHR的最佳去除率为98%。我们认为渗透压剂能够通过减少病毒颗粒周围的水化层来使疏水性无包膜和包膜病毒颗粒发生絮凝,从而促进病毒聚集。既然我们已经证明了保护性渗透压剂能使病毒絮凝,那么这种方法有可能成为未来疫苗的平台纯化工艺。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验